This is your blog intro text.
Rep. Donna McDowell White welcomes attendees NCBIO President Laura Gunter Scott Uknes, Ph.D., co-founder and co-CEO of AgBiome John Fleming, a farmer and partner with Fleming Brothers Farms, LLC in Halifax Sinnovatek President and CEO Michael Druga T. Y. Baker and... Continue Reading
NC Secretary of Commerce Machelle Sanders North Carolina Secretary of Commerce Machelle Baker Sanders encouraged the life sciences industry to be an active participant in shaping the state’s economic plan during the quarterly meeting of the NCBIO Biotech Manufacturer’s Forum held... Continue Reading
BIO: Where things stand with TRIPS waiver It’s been a while since we’ve talked about what’s going on at the WTO. Here’s the latest news—and why the proposed waiver of vaccine IP is still a bad idea. The status: The World Trade Organization is still... Continue Reading
Representatives from G1 Therapeutics, United Therapeutics and Thermo Fisher Scientific shared insights from their companies with members of the North Carolina General Assembly's Life Science Caucus on during its meeting held Wednesday, July 21. Caucus co-chairs Sen. Mike Woodard, Sen.... Continue Reading
When it comes to creating lab space for a new or established business, getting your team together early and allowing plenty of time to plan are the keys to success, according to panelists assembled for NCBIO’s Lab Space Forum held online Tuesday, July 13. The pandemic has caused... Continue Reading
Laura Gunter Laura Gunter, M.B.A, has been selected as the new president of NCBIO, the N.C. Biosciences Organization, succeeding longtime president Sam Taylor who died in February. Gunter has served as the organization’s executive vice president since 2020 and has filled the executive... Continue Reading
BIO: How the PASTEUR Act would support antibiotic R&D The PASTEUR Act, legislation designed to make research and development of new antibiotics economically viable, was reintroduced in Congress last week with bipartisan support. Here’s what it would do and why it... Continue Reading
Government price fixing for U.S. medicines will cost lives, jobs, innovation Legislation that fixes prices for prescription medicines would limit patients’ access to new treatments while doing nothing to lower prices at the pharmacy counter, according to a new analysis released by... Continue Reading
Vaccine patent waiver breaks faith with American companies, stifles innovation NCBIO is extremely disappointed that the Biden administration has chosen to support waiving critical intellectual property protections for U.S. COVID-19 vaccines. This decision, known as a TRIPS waiver,... Continue Reading
BIO President and CEO Michelle McMurry-Heath, M.D., Ph.D., sent a letter April 19 to U.S. Trade Representative Ambassador Katherine Tai to explain why the WTO’s proposed “TRIPS waiver” would have global health and economic consequences as the pandemic rages on. India, South... Continue Reading
A new executive order from the Trump administration that slashes Medicare payments to hospitals and physicians for certain medicines will hurt patients’ access to care and financially stress already overburdened hospitals and innovation-based pharmaceutical companies, according to NCBIO, the... Continue Reading
